Cargando…
Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
INTRODUCTION: The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as assessed by SIB factor scores, in patients with moderately severe-to-severe A...
Autores principales: | Ferris, Steven, Karantzoulis, Stella, Somogyi, Monique, Meng, Xiangyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978681/ https://www.ncbi.nlm.nih.gov/pubmed/24351447 http://dx.doi.org/10.1186/alzrt229 |
Ejemplares similares
-
A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia
por: Farlow, Martin R., et al.
Publicado: (2013) -
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
por: Ferris, Steven, et al.
Publicado: (2013) -
Reliability and validity of the severe impairment battery in Taiwanese patients with moderate to severe Alzheimer’s disease
por: Huang, Mao-Hsuan, et al.
Publicado: (2020) -
The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease
por: Farlow, M.R., et al.
Publicado: (2011) -
Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer’s disease
por: Micca, Joseph L, et al.
Publicado: (2014)